유럽 ​​난소암 시장 – 2023-2030

Europe Ovarian Cancer Market - 2023-2030

상품코드DMPH6258
발행기관DataM Intelligence
발행일2023.02.14
페이지 수200 Pages
포맷PDF + EXCEL
커버리지Europe

₩5,625,000 – ₩10,875,000

보고서 요약(국문)

시장 개요
유럽의 난소암 시장 규모는 2022년 XX억 달러였으며, 예측 기간(2023~2030년) 동안 연평균 XX%의 성장률을 기록하며 XX억 달러에 이를 것으로 예상됩니다.
난소암은 치명적인 부인과 암으로, 전 세계 여성에게서 일곱 번째로 흔한 암입니다. 대부분의 난소암 환자는 치료가 가장 어려운 진행성 단계에서 진단됩니다. 난소암 치료에는 일반적으로 화학요법과 수술이 사용됩니다.
시장 동향
유럽 난소암 진단 및 치료 시장 성장을 이끄는 주요 요인은 고령 여성 인구 증가, 난소암 발병률 증가, 그리고 난소암 치료를 위한 병용 요법 사용 증가입니다.
난소암 발병률 증가와 신제품 승인은 유럽 시장 성장을 견인할 것으로 예상됩니다.

연구진은 2022년 EU 국가에서 약 26,500명의 여성이 난소암으로 사망했고, 영국에서는 4,000명 이상이 사망한 것으로 추정했습니다. 인구의 연령 분포 차이를 고려하여 연령 표준화 사망률을 계산한 결과, EU와 영국에서 각각 인구 10만 명당 4.32명과 4.57명이었습니다. 또한, 난소암 발병률은 55세에서 64세 여성에서 높게 나타납니다. 2021년 5월 OCRA에서 발표한 논문에 따르면, 난소암 진단 사례의 3분의 2 이상이 55세 이상입니다. 난소암의 주요 증상으로는 복부 팽만감, 골반 및 복부 통증, 식사 곤란, 배뇨 장애 등이 있습니다. 2022년 2월 NCBI에서 발표한 논문에 따르면, 난소암은 유럽 여성에게 다섯 번째로 흔한 암입니다. 또한, GLOBOCAN의 2020년 추산에 따르면 유럽에서는 2020년에 약 74,592건의 새로운 난소암 사례가 발생했습니다. 암 발병률 증가에 따라 효과적인 치료에 대한 수요가 증가하고 있습니다.
또한, 유럽의 제품 승인은 예측 기간 동안 시장 성장에 기여할 것으로 예상됩니다. 예를 들어, 2022년 5월 INEX Innovative는 난소 낭종 내 암을 진단하는 OvaCis 신속 검사에 대해 CE-IVD 인증을 획득했습니다. 따라서 유럽에서 고령 여성의 난소암 발병률 증가와 제품 승인 증가는 예측 기간 동안 시장 성장을 견인할 것으로 예상됩니다.
하지만 유럽에서 만성 난소암 치료 비용이 높은 것은 유럽 난소암 시장 성장을 저해하는 요인입니다.

유럽의 높은 난소암 치료 비용은 예측 기간 동안 시장 성장을 저해하는 요소로 작용할 것입니다. 예를 들어, 폴란드에서 난소암 치료 비용은 복강경 자궁적출술의 경우 3,800유로부터 시작합니다.
코로나19의 영향
코로나19 팬데믹은 전 세계적으로 부인과 암 진료 서비스 및 치료 경로를 크게 재편하고 업무 방식을 변화시켰습니다. 의료진은 자원/역량 및 인력 부족에도 불구하고 취약한 환자를 감염으로부터 보호하면서 치료를 제공하기 위해 적응해야 했습니다. 국제 부인과 암 커뮤니티는 수정된 임상 진료 지침을 도입했습니다. 재택근무, 병원 방문 감소, 정기적인 코로나19 검사, 코로나19 감염 위험이 없는 수술실/허브 사용을 통해 복잡한 암 치료를 지속적이고 안전하게 제공할 수 있었으며, 다학제 종양 위원회의 의사 결정을 안내하기 위해 암 치료 우선순위가 설정되었습니다. 첫 번째 유행 기간 동안 약 230만 건의 암 수술이 연기되거나 취소되었으며, 많은 환자들이 암 진행 및 코로나19 감염에 대한 상당한 불안/우려를 표했습니다. 코로나19 관련 임상 시험이 우선시되었지만, 다른 암 임상 시험/연구 활동의 참여자 모집은 크게 감소했습니다. 결과적으로 발생하는 프로토콜 위반이 결과에 미치는 영향은 아직 규명되지 않았습니다. 회복 기간 동안 의료 서비스는 향후 감염 급증에 대처하고, 치료 변경 또는 지연으로 인한 많은 환자 적체를 해결하며, 검진 및 예방 서비스를 유지하기 위해 역량과 유연성을 유지해야 합니다.
세그먼트 분석
상피성 난소암은 예측 기간(2022-2029년) 동안 난소암 시장에서 더 큰 비중을 차지할 것으로 예상됩니다.
상피성 난소암은 2021년 세계 시장을 지배했습니다. 상피성 암은 가장 흔한 유형의 난소암이므로 예측 기간(2022-2029년) 동안에도 유사한 추세를 보일 것으로 예상됩니다. 현재 많은 임상 연구가 진행 중입니다. 예를 들어, 영국 암 연구소(Cancer Research UK)에 따르면 난소 종양의 약 90%가 상피성 종양이며, ClinicalTrials.Gov에 따르면 상피성 난소암에 대한 200건 이상의 중재 연구가 진행 중입니다. 몇 가지 예로는 재발성 난소암 치료를 위한 고온 복강 내 화학요법(HIPEC) 평가를 위한 3상 무작위 연구, p53 변이 상피성 난소암 환자에서 조기 재발(3개월 미만) 또는 표준 1차 치료 중 진행된 환자를 대상으로 Wee-1 억제제 MK-1775와 카보플라틴 병용 요법을 평가하는 2상 약물 연구, 진행성 재발성 상피성 난소암 환자에서 베바시주맙, 올라파립, 두르발루맙(MEDI 4736) 병용 요법의 안전성 및 효능 평가를 위한 GINECO 2상 임상시험, 미르베툭시맙의 3상 단일군 연구 등이 있습니다. 소라브탄신은 백금 내성, 진행성 고등급 상피성 난소암, 원발성 복막암, 또는 엽산 수용체 알파 발현이 높은 나팔관암 등 다양한 암종에 효과가 있는 것으로 알려져 있습니다. 이처럼 상피성 난소암에 대한 연구와 발병 사례가 증가함에 따라 예측 기간 동안 유럽 난소암 시장에서 상피성 난소암이 주도적인 위치를 차지할 것으로 예상됩니다.
지역 분석
영국은 유럽 난소암 시장을 주도할 것으로 전망됩니다.
영국은 높은 난소암 발병률과 많은 임상 시험 진행으로 인해 예측 기간 동안 상당한 성장을 보일 것으로 예상됩니다. GLOBOCAN 2020 자료에 따르면 2020년 영국의 난소암 발병 건수는 약 6,065건이었습니다. 미국에서 난소암 발병률이 높은 것은 영국 시장의 성장을 견인할 것으로 예상됩니다. 또한, 영국에서 난소암 진단 기술이 발전하고 있는 것도 시장 확장에 기여할 것으로 전망됩니다. 예를 들어, 2022년 5월 맨체스터, 버밍엄, 엑서터 대학교는 혈액에서 발견되는 인간 부고환 단백질 4(HE4)가 난소암을 보다 정확하게 진단하고, 불필요하고 침습적인 생검 및 신체검사와 같은 시술을 피하는 데 도움이 될 수 있는지에 대한 연구를 진행했습니다. 이러한 발전은 예측 기간 동안 영국 시장의 성장에 기여할 것으로 예상됩니다.
더불어, 미국에서 난소암 치료제가 보급되고 있는 것도 시장 성장을 촉진할 것으로 예측됩니다. 예를 들어, 2021년 1월 테사로(Tesaro)에서 판매하는 제줄라(Zejula)가 진행성 난소암 유지 요법으로 영국에서 사용 가능하게 되었습니다. 따라서 위에서 언급한 요인들이 영국 시장의 예측 기간 동안 성장을 견인할 것으로 예상됩니다.
경쟁 환경
유럽 난소암 시장의 주요 기업으로는 AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffman-La Roche Ltd, GlaxoSmithKline PLC, Johnson and Johnson, Amgen Inc., Amneal Pharmaceuticals, Siemens Healthineers AG 등이 있습니다. 이들 주요 기업은 신제품 출시, 인수합병, 파트너십, 협력 등 다양한 전략을 통해 유럽 난소암 시장의 성장에 기여하고 있습니다. 예를 들어,
Amgen Inc.
개요:
Amgen Inc.는 심각한 질병 치료제를 발견, 개발, 제조 및 판매하는 독립적인 생명공학 제약 회사입니다. 이 회사는 오로지 인체 치료제에만 집중하며 세포 및 분자 생물학의 발전을 기반으로 혁신적인 신약을 개발합니다.

제품 포트폴리오:
회사의 포트폴리오에는 트레바나닙(AMG 386)과 트리노바-1이 포함되어 있습니다.
유럽 난소암 보고서는 약 40개 이상의 시장 데이터 표, 45개 이상의 그림, 그리고 약 200페이지 분량의 자료를 제공합니다.

보고서 요약(영어 원문)

Market Overview
The Europe ovarian cancer size was valued at US$ XX billion in 2022 and is estimated to reach US$ XX billion, growing at a CAGR of XX% during the forecast period (2023-2030).
Ovarian cancer is a deadly gynecological cancer and is the seventh most common cancer in women globally. Most women with ovarian cancer are diagnosed at the advanced stage, which is the most challenging to treat. Chemotherapy and Surgery are usually used in the treatment of ovarian cancer.
Market Dynamics
The major factors that drive the European ovarian cancer diagnostics and therapeutics market are the increasing geriatric women population, the rise in ovarian cancer cases, and the increasing use of combination therapies to treat ovarian cancer.
The growing cases of ovarian cancer and new product approvals are predicted to drive Europe’s market growth.
The researchers estimated that about 26,500 women died of ovarian cancer in EU countries in 2022 and over 4,000 in the UK. After modifying for distinctions in age dispersal in the population, the age-standardized rate of casualties was 4.32 and 4.57 women per 100,000 in the EU and UK, respectively. Moreover, the incidence of ovarian cancer is elevated in women aged 55 to 64. Also concerned with the article published by OCRA in May 2021, over two-thirds of ovarian cancer diagnosed cases are 55 years or older. The primary signs of ovarian cancer enclose bloating, pelvic and abdominal pain, difficulty eating, and urinary manifestations. According to NCBI's article published in February 2022, ovarian cancer is the fifth most ordinary cancer in Europe for females. Additionally, according to the GLOBOCAN estimates for 2020, Europe registered around 74,592 new ovarian cancer cases in 2020. With the growing load of cancer, there is an increased requirement for efficacious treatment.
In addition, European product authorizations are anticipated to contribute to market growth during the forecast period. For example, in May 2022, INEX Innovative obtained CE-IVD certification for its OvaCis Rapid Test for detecting cancer in ovarian cysts. Therefore, the growing cases of ovarian cancer among aging females in Europe and rising product approvals are estimated to drive the market in the forecast period.
The high cost of chronic ovarian cancer treatment in Europe is restraining the Europe Ovarian Cancer market growth.
However, the high cost of ovarian cancer treatment in Europe is hampering the market growth in the forecast period. For instance, the price of ovarian cancer treatment in Poland Laparoscopic hysterectomy in Polish clinics starts at 3,800 euros.
COVID-19 Impact.
The COVID-19 pandemic resulted in the significant reconfiguration of gynecologic cancer services and care pathways across the globe, with a transformation of working practices. Services had to adapt to protect vulnerable patients from infection while providing care despite reduced resources/capacity and staffing. The international gynecologic cancer community introduced modified clinical care guidelines. Remote working, reduced hospital visiting, routine COVID-testing, and use of COVID-free surgical areas/hubs enabled the ongoing and safe delivery of complex cancer care, with priority levels for cancer treatments established to guide decision-making by multidisciplinary tumor boards. Some 2.3 million cancer surgeries were delayed or canceled during the first peak, with many patients reporting significant anxiety/concern for cancer progression and COVID infection. Although COVID trials were prioritized, recruitment to other cancer trials/research activity was significantly reduced. The impact of resultant protocol deviations on outcomes remains to be established. During the recovery, healthcare services must maintain capacity and flexibility to manage future surges of infection, address the large backlog of patients with altered or delayed treatments, and salvage screening and prevention services.
Segment Analysis
Epithelial ovarian cancer is expected to have a greater grasp of the Ovarian Cancer market during the forecast period (2022-2029)
Epithelial ovarian cancer dominated the global market in 2021. It is expected to show a similar trend throughout the forecast period (2022-2029), as epithelial cancer is the most common type of ovarian cancer. A large number of clinical research is ongoing. For instance, according to Cancer Research UK, about 90 out of 100 tumors of the ovary (90%) are epithelial, and according to the ClinicalTrails.Gov, over 200 interventional studies are active for epithelial ovarian cancer examples of a few are a phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for treatment of relapse ovarian cancer, a phase II pharmacological study with Wee-1 inhibitor MK-1775 combined with carboplatin in patients with p53 mutated epithelial ovarian cancer and early relapse (< 3 months) or progression during standard first-line treatment, a GINECO phase II trial for the assessment of safety and the efficacy of the Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination in patients with advanced epithelial ovarian cancer in relapse, a phase 3, single-arm study of Mirvetuximab Soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression and many more. Thus, the increasing research on epithelial ovarian cancer and cases of epithelial cancer ensures the dominance of epithelial ovarian cancer over the Europe ovarian cancer market throughout the forecast period.
Geographical Analysis
The U.K is expected to be dominating the Europe ovarian cancer market.
The U.K is anticipated to show substantial growth in the forecast period owing to a high number of ovarian cancer cases registered in the country. Moreover, many clinical trials have been executed in the country. According to data publicized by GLOBOCAN 2020, the incidence of ovarian cancer in the U.K in 2020 was around 6,065 cases. These large incidences of ovarian cancer in the United States are expected to drive the growth of the studied market in the U.K. In addition, the evolution of ovarian diagnostics in the U.K is anticipated to contribute to the expansion of the market. For instance, in May 2022, the Universities of Manchester, Birmingham, and Exeter conducted a study to determine if human epididymis protein 4 (HE4), found in the blood, could assist in determining ovarian cancer more accurately and save other women from unnecessary and often invasive procedures such as biopsies and physical examinations. Such developments are expected to contribute to the market's growth during the forecast period in the U.K.
Furthermore, the availability of ovarian cancer therapeutics in the United States is predicted to push the market's growth. For instance, in January 2021, Zejula, marketed by Tesaro, was available in the U.K as maintenance therapy for advanced ovarian cancer. Thus, the abovementioned factors are expected to drive the market's growth during the U.K's forecast period.
Competitive Landscape
The key players operating in the Europe Ovarian Cancer market are AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffman-La Roche Ltd, GlaxoSmithKline PLC, Johnson and Johnson, Amgen Inc., Amneal Pharmaceuticals, Siemens Healthineers AG, among others. The key players are embracing various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the Ovarian Cancer market in Europe. For instance,
Amgen Inc.
Overview:
Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures, and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and innovates novel medicines based on cellular and molecular biology advances.
Product Portfolio:
The company’s portfolio has Trebananib (AMG 386) TRINOVA-1.
The Europe ovarian cancer report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

상세 목차

Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. The Growing cases of Ovarian Cancer
4.1.1.2. Market Developments
4.1.2. Restraints
4.1.2.1. High Cost
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of Covid-19 on the Market
6.1.1. Before COVID-19 Market Scenario
6.1.2. Present COVID-19 Market Scenario
6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturer’s Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Epithelial Ovarian Cancer
7.2.1. Introduction
7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
7.3. Germ Cell Ovarian Cancer
7.4. Stromal Cell Ovarian Cancer
7.5. Small Cell Ovarian Cancer
8. By Modality
8.1. Modality
8.2. Introduction
8.2.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Modality
8.2.2. Market Attractiveness Index, By Modality
8.2.3. Targeted Therapy*
8.2.4. Introduction
8.2.5. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.2.6. Surgery
8.2.7. Chemotherapy
8.2.8. Immunotherapy
8.2.9. Others
8.3. By Diagnosis Type
8.4. Introduction
8.4.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis Type
8.4.2. Market Attractiveness Index, By Diagnosis Type
8.4.3. Blood Tests
8.4.3.1. Introduction
8.4.3.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
8.4.4. Imaging Tests
8.4.5. Laparoscopy
8.4.6. Colonoscopy
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals and Clinics
9.2.1. Introduction
9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
9.3. Diagnostic Centers
9.4. ASCs
9.5. Cancer Research Centers
9.6. Homecare Setting
10. By Country
10.1. Introduction
10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Country
10.1.2. Market Attractiveness Index, By Country
10.2. Germany
10.2.1. Introduction
10.2.2. Key Country-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Modality
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.3. U.K.
10.3.1. Introduction
10.3.2. Key Country-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Modality
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.4. France
10.4.1. Introduction
10.4.2. Key Country-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Modality
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.5. Italy
10.5.1. Introduction
10.5.2. Key Country-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Modality
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.6. Spain
10.6.1. Introduction
10.6.2. Key Country-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Modality
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
10.7. Rest of Europe
10.7.1. Introduction
10.7.2. Key Country-Specific Dynamics
10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Modality
10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Key Developments and Strategies
11.2. Company Share Analysis
11.3. Product Benchmarking
12. Company Profiles
12.1. Amgen Inc.
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Key Highlights
12.1.4. Financial Overview
12.2. AstraZeneca
12.3. Boehringer Ingelheim
12.4. Bristol Myers Squibb Company
12.5. Eli Lilly and Company
12.6. F. Hoffman-La Roche Ltd
12.7. GlaxoSmithKline PLC
12.8. Johnson and Johnson
12.9. Amneal Pharmaceuticals
12.10. Siemens Healthineers AG
LIST NOT EXHAUSTIVE
13. DataM
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us

언급된 주요 기업들

Amgen Inc., AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffman-La Roche Ltd, GlaxoSmithKline PLC, Johnson and Johnson, Amneal Pharmaceuticals, Siemens Healthineers AG

표 목록 (Tables)

List of Tables Table No. 1 Europe Ovarian Cancer Market Value, By Type, 2022, 2026 & 2030 ($ Million)

Table No. 2 Europe Ovarian Cancer Market Value, By Modality, 2022, 2026 & 2030 ($ Million)

Table No. 5 Europe Ovarian Cancer Market Value, By End User, 2022, 2026 & 2030 ($ Million)

Table No. 6 Europe Ovarian Cancer Market Value, By Country, 2022, 2026 & 2030 ($ Million)

Table No. 7 Europe Ovarian Cancer Market Value, By Type, 2022, 2026 & 2030 ($ Million)

Table No. 8 Europe Ovarian Cancer Market Value, By Type, 2021-2030($ Million)

Table No. 9 Europe Ovarian Cancer Market Value, By Modality, 2022, 2026 & 2030 ($ Million)

Table No. 10 Europe Ovarian Cancer Market Value, By Modality, 2021-2030($ Million)

Table No. 15 Europe Ovarian Cancer Market Value, By End User, 2022, 2026 & 2030 ($ Million)

Table No. 16 Europe Ovarian Cancer Market Value, By End User, 2021-2030($ Million)

Table No. 17 Europe Ovarian Cancer Market Value, By Country, 2022, 2026 & 2030 ($ Million)

Table No. 18 Europe Ovarian Cancer Market Value, By Country, 2021-2030($ Million)

Table No. 19 Germany Ovarian Cancer Market Value, By Type, 2021-2030($ Million)

Table No. 20 Germany Ovarian Cancer Market Value, By Modality, 2021-2030($ Million)

Table No. 23 Germany Ovarian Cancer Market Value, By End User, 2021-2030($ Million)

Table No. 24 The U.K. Ovarian Cancer Market Value, By Type, 2021-2030($ Million)

Table No. 25 The U.K. Ovarian Cancer Market Value, By Modality, 2021-2030($ Million)

Table No. 28 The U.K. Ovarian Cancer Market Value, By End User, 2021-2030($ Million)

Table No. 29 France Ovarian Cancer Market Value, By Type, 2021-2030($ Million)

Table No. 30 France Ovarian Cancer Market Value, By Modality, 2021-2030($ Million)

Table No. 33 France Ovarian Cancer Market Value, By End User, 2021-2030($ Million)

Table No. 34 Italy Ovarian Cancer Market Value, By Type, 2021-2030($ Million)

Table No. 35 Italy Ovarian Cancer Market Value, By Modality, 2021-2030($ Million)

Table No. 38 Italy Ovarian Cancer Market Value, By End User, 2021-2030($ Million)

Table No. 39 Spain Ovarian Cancer Market Value, By Type, 2021-2030($ Million)

Table No. 40 Spain Ovarian Cancer Market Value, By Modality, 2021-2030($ Million)

Table No. 43 Spain Ovarian Cancer Market Value, By End User, 2021-2030($ Million)

Table No. 44 Rest of Europe Ovarian Cancer Market Value, By Type, 2021-2030($ Million)

Table No. 45 Rest of Europe Ovarian Cancer Market Value, By Modality, 2021-2030($ Million)

Table No. 48 Rest of Europe Ovarian Cancer Market Value, By End User, 2021-2030($ Million)

Table No. 49 Amgen Inc.: Overview

Table No. 50 Amgen Inc.: Product Portfolio

Table No. 51 Amgen Inc.: Key Developments

Table No. 52 AstraZeneca: Overview

Table No. 53 AstraZeneca: Product Portfolio

Table No. 54 AstraZeneca: Key Developments

Table No. 55 Boehringer Ingelheim: Overview

Table No. 56 Boehringer Ingelheim: Product Portfolio

Table No. 57 Boehringer Ingelheim: Key Developments

Table No. 58 Bristol Myers Squibb Company: Overview

Table No. 59 Bristol Myers Squibb Company: Product Portfolio

Table No. 60 Bristol Myers Squibb Company: Key Developments

Table No. 61 Eli Lilly and Company: Overview

Table No. 62 Eli Lilly and Company: Product Portfolio

Table No. 63 Eli Lilly and Company: Key Developments

Table No. 64 F. Hoffman-La Roche Ltd: Overview

Table No. 65 F. Hoffman-La Roche Ltd: Product Portfolio

Table No. 66 F. Hoffman-La Roche Ltd: Key Developments

Table No. 67 GlaxoSmithKline PLC: Overview

Table No. 68 GlaxoSmithKline PLC: Product Portfolio

Table No. 69 GlaxoSmithKline PLC: Key Developments

Table No. 70 Johnson and Johnson: Overview

Table No. 71 Johnson and Johnson: Product Portfolio

Table No. 72 Johnson and Johnson: Key Developments

Table No. 73 Amneal Pharmaceuticals: Overview

Table No. 74 Amneal Pharmaceuticals: Product Portfolio

Table No. 75 Amneal Pharmaceuticals: Key Developments

Table No. 76 Siemens Healthineers AG: Overview

Table No. 77 Siemens Healthineers AG: Product Portfolio

Table No. 78 Siemens Healthineers AG: Key Developments

그림 목록 (Figures)

List of Figures Figure No. 1 Europe Ovarian Cancer Market Share, By Type, 2022 & 2030 (%)

Figure No. 2 Europe Ovarian Cancer Market Share, By Modality, 2022 & 2030 (%)

Figure No. 5 Europe Ovarian Cancer Market Share, By End User, 2022 & 2030 (%)

Figure No. 6 Europe Ovarian Cancer Market Share, By Country, 2022 & 2030 (%)

Figure No. 7 Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 8 Europe Ovarian Cancer Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure No. 9 Epithelial Ovarian Cancer: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 10 Germ Cell Ovarian Cancer: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 11 Stromal Cell Ovarian Cancer: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 12 Small Cell Ovarian Cancer: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 13 Europe Ovarian Cancer Market Y-o-Y Growth, By Modality, 2022-2030 (%)

Figure No. 14 Targeted Therapy: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 15 Surgery: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 16 Chemotherapy: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 17 Immunotherapy: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 18 Others: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 19 Europe Ovarian Cancer Market Y-o-Y Growth, By Diagnosis Type, 2022-2030 (%)

Figure No. 20 Blood Tests: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 21 Imaging Tests: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 22 Laparoscopy: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 23 Colonoscopy: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 24 Others: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 29 Europe Ovarian Cancer Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure No. 30 Hospitals and Clinics: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 31 Diagnostic Centers: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 32 ASCs: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 33 Cancer Research Centers: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 34 Homecare Setting: Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 35 Europe Ovarian Cancer Market Y-o-Y Growth, By Country, 2022-2030 (%)

Figure No. 36 Germany Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 37 Germany Ovarian Cancer Market Share, By Type, 2022 & 2030 (%)

Figure No. 38 Germany Ovarian Cancer Market Share, By Modality, 2022 & 2030 (%)

Figure No. 41 Germany Ovarian Cancer Market Share, By End User, 2022 & 2030 (%)

Figure No. 42 The U.K. Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 43 The U.K. Ovarian Cancer Market Share, By Type, 2022 & 2030 (%)

Figure No. 44 The U.K. Ovarian Cancer Market Share, By Modality, 2022 & 2030 (%)

Figure No. 45 The U.K. Ovarian Cancer Market Share, By Diagnosis Type, 2022 & 2030 (%)

Figure No. 47 The U.K. Ovarian Cancer Market Share, By End User, 2022 & 2030 (%)

Figure No. 48 France Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 49 France Ovarian Cancer Market Share, By Type, 2022 & 2030 (%)

Figure No. 50 France Ovarian Cancer Market Share, By Modality, 2022 & 2030 (%)

Figure No. 53 France Ovarian Cancer Market Share, By End User, 2022 & 2030 (%)

Figure No. 54 Italy Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 55 Italy Ovarian Cancer Market Share, By Type, 2022 & 2030 (%)

Figure No. 56 Italy Ovarian Cancer Market Share, By Modality, 2022 & 2030 (%)

Figure No. 59 Italy Ovarian Cancer Market Share, By End User, 2022 & 2030 (%)

Figure No. 60 Spain Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 61 Spain Ovarian Cancer Market Share, By Type, 2022 & 2030 (%)

Figure No. 62 Spain Ovarian Cancer Market Share, By Modality, 2022 & 2030 (%)

Figure No. 65 Spain Ovarian Cancer Market Share, By End User, 2022 & 2030 (%)

Figure No. 66 Rest of Europe Ovarian Cancer Market Value, 2021-2030($ Million)

Figure No. 67 Rest of Europe Ovarian Cancer Market Share, By Type, 2022 & 2030 (%)

Figure No. 68 Rest of Europe Ovarian Cancer Market Share, By Modality, 2022 & 2030 (%)

Figure No. 71 Rest of Europe Ovarian Cancer Market Share, By End User, 2022 & 2030 (%)

Figure No. 72 Amgen Inc.: Financials

Figure No. 73 AstraZeneca: Financials

Figure No. 74 Boehringer Ingelheim: Financials

Figure No. 75 Bristol Myers Squibb Company: Financials

Figure No. 76 Eli Lilly and Company: Financials

Figure No. 77 F. Hoffman-La Roche Ltd: Financials

Figure No. 78 GlaxoSmithKline PLC: Financials

Figure No. 79 Johnson and Johnson: Financials

Figure No. 80 Amneal Pharmaceuticals: Financials

Figure No. 81 Siemens Healthineers AG: Financials